Back to Journals » Drug Design, Development and Therapy » Volume 7

Successful management of an inadvertent excessive treprostinil overdose

Authors Hohenforst-Schmidt W, Hornig J, Friedel N, Zarogoulidis P, Zarogoulidis K, Brachmann J

Received 15 January 2013

Accepted for publication 12 February 2013

Published 21 March 2013 Volume 2013:7 Pages 161—165

DOI https://doi.org/10.2147/DDDT.S42771

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 7



Wolfgang Hohenforst-Schmidt,1 Juergen Hornig,2 Norbert Friedel,3 Paul Zarogoulidis,1,4 Konstantinos Zarogoulidis,4 Johannes Brachmann1

1II Medical Clinic, Coburg Clinic, University of Würzburg, Coburg, Germany; 2Department of Cardiology, Bayreuth Clinic, University of Erlangen, Bayreuth, Germany; 3Department of Cardiac Surgery, “Bayreuth Clinic”, University of Erlangen, Bayreuth, Germany; 4Pulmonary Department, G Papanikolaou, General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

Abstract: Pulmonary hypertension is defined by 25 mmHg pressure at rest, and 35 mmHg pressure at exercise, in the pulmonary arteries. Hypertension either primary or secondary. The exact prevalence of all types of pulmonary hypertension is not yet known. We present a case of a 58-year-old female patient suffering from CREST syndrome, Raynaud’s syndrome, esophageal motility impairment, and severe pulmonary hypertension who had previously obtained a specially developed implantable pump, named Lenus Pro®, to facilitate continuous parenteral treatment of pulmonary arterial hypertension with treprostinil. Treprostinil is a prostanoid derivative with very stable physiochemical properties which allows subcutaneous treatment of pulmonary arterial hypertension in the outpatient. Treprostinil is normally dosed individually in a range of 0.6 to 50 ng/kg/minute. In the underlying case, a dose of more than 100 mg given over 1 minute is equivalent to a 1000 fold overdose. The patient’s critical condition required installment of a central venous access, full monitoring, sedation, oxygen nasal tube, fluid balance, and parenteral nutrition. The patient could be hemodynamically stabilized within 24 hours after the overdose. After 6 days of recovery, the patient left the hospital with no remaining health impairment.

Keywords: pulmonary hypertension, ICU, overdose, treprostinil, Raynaud’s syndrome, CREST syndrome

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.